RSV Vaccination in South Korea: Age, Risk and Product Eligibility
Why Korean RSV advice mentions several different ages
In Korea, product approval and a vaccination recommendation answer different questions. Approval defines the population in which a particular product can be used. A professional recommendation considers who should receive vaccination based on disease risk and expected benefit. Neither automatically confirms public funding or stock at a clinic. This guide was checked on 7 October 2026. [1][2][3][4]
RSV can cause serious respiratory disease in older adults and people with certain underlying conditions. It can also worsen existing heart or lung disease. The fact that RSV affects infants does not make adult prevention irrelevant, but adult risk should be assessed individually. [5]
The Korean Society of Infectious Diseases recommendation
The society’s 2026 guidance recommends one dose for adults aged 75 or older, and one dose for adults aged 50–74 at increased risk of severe RSV disease. Being 50 or 60 alone is therefore not the same as meeting the high-risk recommendation. [1]
Examples include chronic heart disease such as heart failure, chronic lung disease, end-stage kidney disease or dialysis, moderate or severe immune compromise, and residence in a nursing facility. Uncomplicated hypertension is excluded from the guideline’s heart-disease category. Diabetes requires a more specific review of complications and treatment; do not classify yourself from the diagnosis name alone. [1]
Current Korean product approvals
Arexvy (아렉스비) is approved for adults aged 60 or older and adults aged 18–59 at increased risk of RSV lower respiratory tract disease. Its indication was changed on 1 July 2026. The label does not recommend its use during pregnancy. [2]
Abrysvo (아브리스보), approved on 13 August 2026, includes those same adult age and risk groups. It also has a maternal indication: one dose during weeks 28–36 of pregnancy to help prevent RSV lower respiratory tract disease in infants through six months of age. The adult and maternal indications should be discussed separately. [3]
mRESVIA, sold under the Korean name 엠레스비아프리필드시린지, is an mRNA RSV vaccine approved on 18 December 2025. Its current Korean indication includes adults aged 60 or older and adults aged 18–59 at increased risk of RSV lower respiratory tract disease. It does not have the maternal indication described above. The adult administration schedule for these products is a single dose. [2][3][4]
Broader product approval does not create a routine recommendation for every adult aged 18 or older. If you fall outside the society’s routine age groups but have a serious condition, ask your treating clinician about your particular situation. [1]
A 2026 document can still contain an older product table
The society’s RSV PDF describes Abrysvo as unapproved in Korea as of February 2026. Its Arexvy table also predates the July indication change. Use the society’s text for the adult recommendation, and the current MFDS product record for the Korean label. Reading only a copied table can miss later changes. [1][2][3]
An approved product may not be available at every clinic. Before travelling to an appointment, ask for the exact product name, whether the clinic has it, whether a consultation is needed first, and the total charge.
Do you need a dose every year?
The Korean society does not currently recommend regular repeat RSV vaccination. Evidence on the need for revaccination and its interval remains limited. If you were vaccinated previously, locate the product and date before booking again. Do not automatically add a different brand or treat RSV vaccination as an annual influenza appointment. [1]
Vaccination can be given throughout the year. The Korean guidance identifies August–October as a useful period considering the usual RSV season. Missing that period does not automatically mean waiting a whole year; the clinician should review your risk and previous doses. [1]
Maternal vaccine and infant antibody are different products
Maternal vaccination aims to generate antibodies in the mother that pass through the placenta. A long-acting monoclonal antibody given directly to an infant supplies antibodies to the baby. These are different preventive approaches and should not be confused with an adult RSV booster. [5]
Korean Abrysvo approval uses weeks 28–36. The U.S. CDC recommendation uses 32 weeks 0 days through 36 weeks 6 days, with September–January administration in most of the continental United States. Do not import those U.S. timing rules as the Korean label. Discuss maternal vaccination and the infant’s plan with the obstetric and pediatric teams. [3][6]
Compare practical suitability, not isolated percentages
Effectiveness percentages from different trials cannot reliably rank products when participants, outcome definitions and follow-up periods differ. Ask how the evidence applies to your age, illness and treatment. Discuss expected reactions, previous severe allergies and any relevant medical history. [1][2][3][4]
Coadministration with other adult vaccines may be possible, but the actual products matter and some combinations increase short-term reactions. Maternal coadministration needs its own review. Severe breathing difficulty, face or throat swelling, or loss of consciousness after vaccination requires emergency assessment. [2][3][4]
A useful request for a Korean clinic
You can say: “I am aged __ and have __. Could you check whether RSV vaccination is recommended for me, the available product, and the total cost?” In Korean: “제 나이와 질환을 기준으로 RSV 예방접종 대상인지, 접종 제품과 총비용을 확인하고 싶습니다.” Include any previous RSV vaccination date.
This is general health information. Your clinician should decide whether vaccination is appropriate and choose its timing. Public support, individual eligibility and the clinic’s current supply require separate confirmation.
Related published guides
- Flu Shots in Korea 2026–2027: Dates and Eligibility
- Can You Get Flu and COVID Vaccines at the Same Time?
Sources
- 성인 호흡기세포융합바이러스 백신 접종 권고안 · 대한감염학회 · 2026 개정 / 제품표 2026-02 기준 · 2026-10-07 KST
- 아렉스비주 의약품 제품정보 · 식품의약품안전처 · 효능효과 변경 2026-07-01 · 2026-10-07 KST
- 아브리스보주 의약품 제품정보 · 식품의약품안전처 · 최초허가 2026-08-13 · 2026-10-07 KST
- 엠레스비아프리필드시린지 의약품 제품정보 · 식품의약품안전처 · 최초허가 2025-12-18 · 2026-10-07 KST
- Respiratory syncytial virus (RSV) · WHO · 2025-12-19 · 2026-10-07 KST
- RSV Vaccine Guidance for Pregnant Women · CDC · 2024-08-30 · 2026-10-07 KST
